Systems to promote healing at a site of a medical device

• US 10,576,185 B2
• Filed: 06/28/2019
• Issued: 03/03/2020
• Est. Priority Date: 12/29/2016
• Status: Active Grant

• Current Assignee: Tempo Therapeutics, Inc.
• Original Assignee: Tempo Therapeutics, Inc.
• Inventors: Weaver, Westbrook, Deshayes, Stephanie, Timko, Samuel
• Primary Examiner(s): Azpuru, Carlos A
• Assistant Examiner(s): Hagopian, Casey S
• Application Number:
  US16/457,517
• Publication Number:
  US 20190321520A1
• Time in Patent Office: 249 Days
• Field of Search: None
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 2400/06 Flowable or injectable implant compositions
• CPC Class Codes: A61L 2400/12 Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• CPC Class Codes: A61L 2430/30 for muscle reconstruction
• CPC Class Codes: A61L 27/14 Macromolecular materials
• CPC Class Codes: A61L 27/16 obtained by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/18 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/52 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: B01J 13/0065 containing an organic phase
• CPC Class Codes: B01J 13/0069 Post treatment
• CPC Class Codes: B01J 19/0093 Microreactors, e.g. miniaturised or microfabricated reactors laboratory containers with capillary fluid transport in microfabricated channels or chambers B01L3/5027

Abstract

Disclosed herein are systems for promoting healing of a wound or surgical incision at a medical device site (e.g., implanted medical device) in a subject, by administering a microporous gel to the medical implant site. Also disclosed are systems for the treatment and prevention of infection at a medical implant site in a subject, by administering a microporous gel to the medical implant site. The microporous gel may be fluidic during application and annealed or crosslinked after application. The microporous gels may contain various therapeutic agents, including antibiotics and analgesics, throughout the gel.

Claims

1. A method of delivering a hydrogel system to an in vivo site of an implanted medical device in a subject, the method comprising:

(a) implanting a medical device in an in vivo site of a subject;

(b) delivering a hydrogel into the in vivo site of the implanted medical device by injection, the hydrogel comprising;

(1) a network of microgel particles, each microgel particle having a median diameter of about 10 micrometers (μ

m) to about 500 μ

m and comprising;

(i) annealing components, wherein an annealing component is configured to bond to an adjacent annealing component; and

(ii) a backbone polymer; and

(2) a plurality of interconnected pores, the plurality of interconnected pores having a median size of at least 10 μ

m;

(c) delivering an annealing agent to the in vivo site of the implanted medical device; and

(d) exposing the hydrogel and the annealing agent to light causing the annealing components to bond to adjacent annealing components to stabilize the network of microgel particles comprising the plurality of interconnected pores, the stabilized hydrogel comprising;

(1) an inner surface molded to a shape of the implanted medical device;

(2) an outer surface molded to a shape of the in vivo site of the implanted medical device in the subject; and

(3) a compressive modulus of between 1,500 and 200,000 Pascal (Pa).

2. The method of claim 1, wherein the implanted medical device is a cardiac implantable electronic device.

3. The method of claim 1, wherein the implanted medical device is a neural implantable electronic device.

4. The system method of claim 1, wherein the annealing component is a functional group selected from a vinyl sulfone, thiol, amine, imidazole, aldehyde, ketone, hydroxyl, azide, alkyne, vinyl, alkene, maleimide, carboxyl, N-hydroxysuccinimide (NHS) ester, isocyanate, isothiocyanate, hydroxylamine, thione, catechol, sialic acid, boronic acid, molecular cage, adamantane, biotin, and streptavidin.

5. The method of claim 1, wherein the backbone polymer comprises poly(ethylene glycol).

6. The method of claim 1, wherein the annealing component is covalently bonded to the adjacent annealing component.

7. The method of claim 1, wherein the annealing component is bonded to the adjacent annealing component through a non-covalent bond selected from an electrostatic interaction, a hydrogen bond, a cation-n, n-n stack, a metal-ligand bond, a van der Waals interaction, and a non-covalent host-guest inclusion complex.

8. The method of claim 1, wherein the backbone polymer is functionalized with a functional group selected from a vinyl sulfone, thiol, amine, imidazole, aldehyde, ketone, hydroxyl, azide, alkyne, vinyl, alkene, maleimide, carboxyl, N-hydroxysuccinimide (NHS) ester, isocyanate, isothiocyanate, hydroxylamine, thione, catechol, sialic acid, boronic acid, molecular cage, adamantane, biotin, and streptavidin.

9. The method of claim 1, further comprising tissue of the subject at the site of the implanted medical device integrated into the hydrogel via the plurality of interconnected pores.

10. The method of claim 1, wherein 10-40% of the hydrogel comprises the plurality of interconnected pores.

11. The method of claim 1, wherein the annealing agent is selected from a radical initiator, a radical transfer agent, a proton transfer agent, an electron transfer agent, a reducing agent, an oxidizing agent, a base, an acid and an enzyme.

12. The method of claim 1, wherein the hydrogel further comprises a therapeutic agent.

13. The method of claim 1, wherein the in vivo site of the implanted medical device is soft tissue.

14. The method of claim 1, wherein the in vivo site of the implanted medical device is a neural tissue.

15. The method of claim 1, further comprising stabilizing the implanted medical device in the in vivo site for about 50 days following delivery.

16. The method of claim 1, further comprising reducing a risk of developing fibrosis in the subject at the in vivo site of the implanted medical device.

17. The method of claim 1, wherein the hydrogel comprises a therapeutic agent, and the method further comprises releasing from the hydrogel the therapeutic agent at the in vivo site of the implanted medical device.

18. The method of claim 1, wherein the hydrogel and the annealing agent are delivered simultaneously to the in vivo site of the implanted medical device.

19. The method of claim 1, wherein the annealing agent is Eosin Y.